Ovarian Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Ovarian Cancer Diagnostic Tests include assays of mostly antibodies released in response to a ovarian cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Ovarian Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Ovarian Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:

Extensive coverage of the Ovarian Cancer Diagnostic Tests under development

Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates

Reviews of major players involved in the pipeline product development.

Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Ovarian Cancer Diagnostic Tests pipeline products.

Review of Recent Developments in the segment / industry

The Ovarian Cancer Diagnostic Tests Pipeline Assessment report enables you to:

Access significant competitor information, analysis, and insights to improve your R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Glaucoma Drainage Device sunder development

Formulate market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

The major companies covered in the “Ovarian Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025

• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports

• 64,000+ medical equipment company profiles

• 5,600+ company profiles of medical equipment manufacturers in China and India

• 2,200+ company profiles of medical equipment manufacturers in Japan

• 1,200+ companies’ revenue splits and market shares

• 1,600+ quarterly and annual medical equipment company financials

• 850+ medical equipment company SWOTs

• 28,000+ pipeline product profiles

• 56,400+ marketed product profiles

• 47,000+ clinical trials

• 41,500+ trial investigators

• 7,000+ reports on companies with products in development

• 44,000+ deals in the medical equipment industry

• 1,100+ surgical and diagnostic procedures by therapy area

• 50+ key healthcare indicators by country

• 431,000+ Themes Content Items

• 600+ Influencers

• 1,900+ Analysts & Researchers

• 0.5m+ Community Members

• 141,000+ Macroeconomic Indicators

• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:

https://medical.globaldata.com/home.aspx

Custom Requirements

Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

Extensive coverage of the Ovarian Cancer Diagnostic Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to:

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product’s current stage of development, territory and estimated launch date

Companies mentioned

2cureX AB

A&G Pharmaceutical Inc

AB ANALITICA srl

Accudava Inc

Adaptive Biotechnologies Corp

Almac Diagnostic Services Ltd

Angle Biosciences Inc

Anixa Diagnostics Corporation

AroCell AB

Arrayit Corporation

Aspira Labs

Aurelium BioPharma Inc.

Avant Diagnostics Inc

Ayanda Biosystems SA (Inactive)

BARD1 Life Sciences Ltd

Becton Dickinson and Co

BioFluidica Microtechnologies LLC

Bioindustry Park Silvano Fumero SpA

Brigham and Women's Hospital

Captis Biotechnology Inc

Celcuity Inc

Celula Inc

Ceres Nanosciences Inc

Chronix Biomedical Inc

Clarient Inc

ClavGen Therapeutics LLC

Cleveland Diagnostics Inc.

Courtagen Life Sciences Inc

Dana-Farber Cancer Institute Inc

Diazyme Laboratories Inc

Entopsis LLC

Eventus Diagnostics Inc (Inactive)

Exact Sciences Corp

Exiqon AS

Exosomics Siena SpA

Fahy Gurteen UK Ltd

French National Institute of Health and Medical Research

Ganymed Pharmaceuticals AG

Georgia Institute of Technology

Gina-Life Diagnostics Ltd

GlycoZym USA Inc

H. Lee Moffitt Cancer Center & Research Institute Inc

HealthTell Inc

Hide and Seq

Hudson Institute of Medical Research

Ikonisys Inc

INEX Innovate Pte Ltd

InterGenetics Inc

InterVenn BioSciences

Johns Hopkins University

KIYATEC Inc

Lab Discoveries Ltd

Laboratorios SALVAT SA

Louisville Bioscience Inc (Inactive)

MabCure Inc

Massachusetts Institute of Technology

MDNA Life Sciences Inc

Metabolon Inc

Milagen Inc

MyCartis NV

Nagoya University

Nanostics Inc

Novel Bio-spectrum Technologies Inc (Inactive)

Olink Proteomics AB

Olympia Diagnostics Inc

Oncgnostics GmbH

Oncimmune (USA) LLC

Oncology Venture U.S. Inc

Orion Genomics LLC

OTraces Inc

Peregrine Pharmaceuticals, Inc.

Peri Rx Inc

Precision Biologics Inc

Preora Healthcare Inc

Princess Margaret Cancer Centre

Protagen AG

Proteomika (Inactive)

Provista Diagnostics Inc

Queen's University Belfast

Rosetta Genomics Ltd

Shenzhen Mindray Bio-Medical Electronics Co Ltd

SomaLogic Inc

Soricimed Biopharma Inc

Stage I Diagnostics Inc

StageZero Life Sciences Ltd

SurExam Life Science & Technology Co.

Taizhou ZECEN Biotech Co Ltd

Target Discovery Inc

Teva Pharmaceutical Industries Ltd

The University of Manchester

Tradewind BioScience Inc

Treos Bio Inc

University of Adelaide

University of Arkansas for Medical Sciences

University of California San Diego

University of Chicago

University of Montreal

University of Pittsburgh

University of South Florida

University of Texas MD Anderson Cancer Center

US Biomarkers Inc

Vermillion Inc

Vitruvian Biomedical Inc

Wistar Institute

Yale University

ZORA Biosciences Oy

Table of Contents

1 Table of Contents 2

1.1 List of Tables 8

1.2 List of Figures 14

2 Introduction 15

2.1 Ovarian Cancer Overview 15

3 Products under Development 16

3.1 Ovarian Cancer – Pipeline Products by Stage of Development 16

3.2 Ovarian Cancer – Pipeline Products by Territory 17

3.3 Ovarian Cancer – Pipeline Products by Regulatory Path 18

3.4 Ovarian Cancer – Pipeline Products by Estimated Approval Date 19

3.5 Ovarian Cancer – Ongoing Clinical Trials 20

4 Ovarian Cancer – Pipeline Products under Development by Companies 21

4.1 Ovarian Cancer Companies – Pipeline Products by Stage of Development 21

4.2 Ovarian Cancer – Pipeline Products by Stage of Development 25

5 Ovarian Cancer Companies and Product Overview 29

5.1 2cureX AB Company Overview 29

5.1.1 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview 29

5.2 A&G Pharmaceutical Inc Company Overview 30

5.2.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.3 AB ANALITICA srl Company Overview 31

5.3.1 AB ANALITICA srl Pipeline Products & Ongoing Clinical Trials Overview 31

5.4 Accudava Inc Company Overview 32

5.4.1 Accudava Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.5 Adaptive Biotechnologies Corp Company Overview 34

5.5.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 34

5.6 Almac Diagnostic Services Ltd Company Overview 35

5.6.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 35

5.7 Angle Biosciences Inc Company Overview 38

5.7.1 Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.8 Anixa Diagnostics Corporation Company Overview 39

5.8.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 39

5.9 AroCell AB Company Overview 44

5.9.1 AroCell AB Pipeline Products & Ongoing Clinical Trials Overview 44

5.10 Arrayit Corporation Company Overview 45

5.10.1 Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 45

5.11 Aspira Labs Company Overview 46

5.11.1 Aspira Labs Pipeline Products & Ongoing Clinical Trials Overview 46

5.12 Aurelium BioPharma Inc. Company Overview 50

5.12.1 Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

5.13 Avant Diagnostics Inc Company Overview 53

5.13.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.14 Ayanda Biosystems SA (Inactive) Company Overview 54

5.14.1 Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 54

5.15 BARD1 Life Sciences Ltd Company Overview 55

5.15.1 BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

5.16 Becton Dickinson and Co Company Overview 56

5.16.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 56

5.17 BioFluidica Microtechnologies LLC Company Overview 57

5.17.1 BioFluidica Microtechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview 57

5.18 Bioindustry Park Silvano Fumero SpA Company Overview 58

5.18.1 Bioindustry Park Silvano Fumero SpA Pipeline Products & Ongoing Clinical Trials Overview 58

5.19 Brigham and Women's Hospital Company Overview 59

5.19.1 Brigham and Women's Hospital Pipeline Products & Ongoing Clinical Trials Overview 59

5.20 Captis Biotechnology Inc Company Overview 60

5.20.1 Captis Biotechnology Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.21 Celcuity Inc Company Overview 61

5.21.1 Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 61

5.22 Celula Inc Company Overview 62

5.22.1 Celula Inc Pipeline Products & Ongoing Clinical Trials Overview 62

5.23 Ceres Nanosciences Inc Company Overview 63

5.23.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 63

5.24 Chronix Biomedical Inc Company Overview 64

5.24.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.25 Clarient Inc Company Overview 65

5.25.1 Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.26 ClavGen Therapeutics LLC Company Overview 66

5.26.1 ClavGen Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 66

5.27 Cleveland Diagnostics Inc. Company Overview 67

5.27.1 Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 67

5.28 Courtagen Life Sciences Inc Company Overview 68

5.28.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 68

5.29 Dana-Farber Cancer Institute Inc Company Overview 69

5.29.1 Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 69

5.30 Diazyme Laboratories Inc Company Overview 70

5.30.1 Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.31 Entopsis LLC Company Overview 73

5.31.1 Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 73

5.32 Eventus Diagnostics Inc (Inactive) Company Overview 74

5.32.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 74

5.33 Exact Sciences Corp Company Overview 75

5.33.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 75

5.34 Exiqon AS Company Overview 76

5.34.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 76

5.35 Exosomics Siena SpA Company Overview 77

5.35.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 77

5.36 Fahy Gurteen UK Ltd Company Overview 78

5.36.1 Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.37 French National Institute of Health and Medical Research Company Overview 79

5.37.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 79

5.38 Ganymed Pharmaceuticals AG Company Overview 80

5.38.1 Ganymed Pharmaceuticals AG Pipeline Products & Ongoing Clinical Trials Overview 80

5.39 Georgia Institute of Technology Company Overview 81

5.39.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 81

5.40 Gina-Life Diagnostics Ltd Company Overview 82

5.40.1 Gina-Life Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 82

5.41 GlycoZym USA Inc Company Overview 83

5.41.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 83

5.42 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 84

5.42.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 84

5.43 HealthTell Inc Company Overview 85

5.43.1 HealthTell Inc Pipeline Products & Ongoing Clinical Trials Overview 85

5.44 Hide and Seq Company Overview 86

5.44.1 Hide and Seq Pipeline Products & Ongoing Clinical Trials Overview 86

5.45 Hudson Institute of Medical Research Company Overview 87

5.45.1 Hudson Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 87

5.46 Ikonisys Inc Company Overview 88

5.46.1 Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 88

5.47 INEX Innovate Pte Ltd Company Overview 89

5.47.1 INEX Innovate Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

5.48 InterGenetics Inc Company Overview 90

5.48.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 90

5.49 InterVenn BioSciences Company Overview 91

5.49.1 InterVenn BioSciences Pipeline Products & Ongoing Clinical Trials Overview 91

5.50 Johns Hopkins University Company Overview 94

5.50.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 94

5.51 KIYATEC Inc Company Overview 98

5.51.1 KIYATEC Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.52 Lab Discoveries Ltd Company Overview 99

5.52.1 Lab Discoveries Ltd Pipeline Products & Ongoing Clinical Trials Overview 99

5.53 Laboratorios SALVAT SA Company Overview 100

5.53.1 Laboratorios SALVAT SA Pipeline Products & Ongoing Clinical Trials Overview 100

5.54 Louisville Bioscience Inc (Inactive) Company Overview 101

5.54.1 Louisville Bioscience Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 101

5.55 MabCure Inc Company Overview 102

5.55.1 MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 102

5.56 Massachusetts Institute of Technology Company Overview 103

5.56.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 103

5.57 MDNA Life Sciences Inc Company Overview 104

5.57.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 104

5.58 Metabolon Inc Company Overview 105

5.58.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 105

5.59 Milagen Inc Company Overview 106

5.59.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 106

5.60 MyCartis NV Company Overview 107

5.60.1 MyCartis NV Pipeline Products & Ongoing Clinical Trials Overview 107

5.61 Nagoya University Company Overview 108

5.61.1 Nagoya University Pipeline Products & Ongoing Clinical Trials Overview 108

5.62 Nanostics Inc Company Overview 109

5.62.1 Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 109

5.63 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 110

5.63.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 110

5.64 Olink Proteomics AB Company Overview 111

5.64.1 Olink Proteomics AB Pipeline Products & Ongoing Clinical Trials Overview 111

5.65 Olympia Diagnostics Inc Company Overview 112

5.65.1 Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 112

5.66 Oncgnostics GmbH Company Overview 113

5.66.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 113

5.67 Oncimmune (USA) LLC Company Overview 114

5.67.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 114

5.68 Oncology Venture U.S. Inc Company Overview 115

5.68.1 Oncology Venture U.S. Inc Pipeline Products & Ongoing Clinical Trials Overview 115

5.69 Orion Genomics LLC Company Overview 116

5.69.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 116

5.70 OTraces Inc Company Overview 117

5.70.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 117

5.71 Peregrine Pharmaceuticals, Inc. Company Overview 118

5.71.1 Peregrine Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 118

5.72 Peri Rx Inc Company Overview 119

5.72.1 Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 119

5.73 Precision Biologics Inc Company Overview 120

5.73.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 120

5.74 Preora Healthcare Inc Company Overview 121

5.74.1 Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 121

5.75 Princess Margaret Cancer Centre Company Overview 122

5.75.1 Princess Margaret Cancer Centre Pipeline Products & Ongoing Clinical Trials Overview 122

5.76 Protagen AG Company Overview 123

5.76.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 123

5.77 Proteomika (Inactive) Company Overview 124

5.77.1 Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 124

5.78 Provista Diagnostics Inc Company Overview 125

5.78.1 Provista Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 125

5.79 Queen's University Belfast Company Overview 126

5.79.1 Queen's University Belfast Pipeline Products & Ongoing Clinical Trials Overview 126

5.80 Rosetta Genomics Ltd Company Overview 127

5.80.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 127

5.81 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 128

5.81.1 Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 128

5.82 SomaLogic Inc Company Overview 129

5.82.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 129

5.83 Soricimed Biopharma Inc Company Overview 130

5.83.1 Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 130

5.84 Stage I Diagnostics Inc Company Overview 132

5.84.1 Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 132

5.85 StageZero Life Sciences Ltd Company Overview 133

5.85.1 StageZero Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 133

5.86 SurExam Life Science & Technology Co. Company Overview 134

5.86.1 SurExam Life Science & Technology Co. Pipeline Products & Ongoing Clinical Trials Overview 134

5.87 Taizhou ZECEN Biotech Co Ltd Company Overview 135

5.87.1 Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 135

5.88 Target Discovery Inc Company Overview 136

5.88.1 Target Discovery Inc Pipeline Products & Ongoing Clinical Trials Overview 136

5.89 Teva Pharmaceutical Industries Ltd Company Overview 137

5.89.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 137

5.90 The University of Manchester Company Overview 138

5.90.1 The University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 138

5.91 Tradewind BioScience Inc Company Overview 139

5.91.1 Tradewind BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 139

5.92 Treos Bio Inc Company Overview 140

5.92.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 140

5.93 University of Adelaide Company Overview 141

5.93.1 University of Adelaide Pipeline Products & Ongoing Clinical Trials Overview 141

5.94 University of Arkansas for Medical Sciences Company Overview 143

5.94.1 University of Arkansas for Medical Sciences Pipeline Products & Ongoing Clinical Trials Overview 143

5.95 University of California San Diego Company Overview 144

5.95.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 144

5.96 University of Chicago Company Overview 145

5.96.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 145

5.97 University of Montreal Company Overview 146

5.97.1 University of Montreal Pipeline Products & Ongoing Clinical Trials Overview 146

5.98 University of Pittsburgh Company Overview 147

5.98.1 University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 147

5.99 University of South Florida Company Overview 148

5.99.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 148

5.100 University of Texas MD Anderson Cancer Center Company Overview 151

5.100.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 151

5.101 US Biomarkers Inc Company Overview 152

5.101.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 152

5.102 Vermillion Inc Company Overview 153

5.102.1 Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview 153

5.103 Vitruvian Biomedical Inc Company Overview 154

5.103.1 Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 154

5.104 Wistar Institute Company Overview 155

5.104.1 Wistar Institute Pipeline Products & Ongoing Clinical Trials Overview 155

5.105 Yale University Company Overview 156

5.105.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 156

5.106 ZORA Biosciences Oy Company Overview 158

5.106.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 158

6 Ovarian Cancer- Recent Developments 159

6.1 Oct 23, 2020: Mentice receives order of total SEK

7.1 million from ABBOTT 159

6.2 Oct 20, 2020: Prescient Therapeutics : September 2020 quarterly update and Appendix 4C 159

6.3 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality 161

6.4 Jun 25, 2020: SEC charges Novartis with FCPA violations 163

6.5 Jun 18, 2020: IncellDx files patent for CCL5/RANTES utility as a diagnostic, prognostic, and therapeutic biomarker in COVID-19 and other cytokine storm conditions 163

6.6 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation 164

6.7 May 27, 2020: At-home screening for ovarian, breast cancers is effective 164

6.8 May 15, 2020: Xencor to present data from four preclinical XmAb 2+1 bispecific antibody and cytokine programs at AACR Virtual Annual Meeting II 166

6.9 May 05, 2020: InMed and Almac Group developing improved cannabinoid production methods 166

6.10 May 04, 2020: StageZero Life Sciences announces enhanced relationship with Phleb-Finders 167

6.11 Apr 29, 2020: Cancer testing and diagnosis suffers sharp downturn, finds Diaceutics 167

6.12 Apr 24, 2020: TruSight Oncology family grows with liquid biopsy and high-throughput assay additions 168

6.13 Apr 16, 2020: Abbott reports first-quarter 2020 results 170

6.14 Mar 06, 2020: 2cureX is accelerating the commercialization of IndiTreat by signing two distributor agreements to prepare for launch in second half of 2020 172

6.15 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors 172

6.16 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 173

6.17 Feb 26, 2020: Adaptive Biotechnologies reports fourth quarter and full year 2019 financial results 175

6.18 Feb 25, 2020: TCS digitally transforms Qiagen’s global research platform to improve user experience with new digital capabilities 176

6.19 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director 177

6.20 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal 177

6.21 Feb 13, 2020: LabCorp announces 2019 fourth quarter and full year results and provides 2020 guidance 177

6.22 Feb 12, 2020: Teva reports fourth quarter and full year 2019 financial results 180

6.23 Feb 11, 2020: Myriad Submits sPMA for myChoice CDx with Lynparza in first-line maintenance therapy in advanced ovarian cancer 188

6.24 Feb 11, 2020: Abbott Laboratories: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officer 188

6.25 Feb 06, 2020: BD announces results for 2020 first fiscal quarter; lowers fiscal 2020 guidance 189

6.26 Feb 06, 2020: Myriad announces leadership transition 190

6.27 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 191

6.28 Feb 05, 2020: UMass Amherst study aims to develop new test for BRCA-positive lactating moms 193

6.29 Jan 29, 2020: Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 194

6.30 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results 200

6.31 Jan 27, 2020: CMS expands coverage of next generation sequencing as a diagnostic tool for patients with breast and ovarian cancer 208

6.32 Jan 22, 2020: Myriad submits sPMA for myChoice CDx with Zejula in first-line platinum responsive advanced ovarian cancer 208

6.33 Jan 22, 2020: Abbott reports fourth-quarter 2019 results; announces strong forecast for 2020 209

6.34 Jan 22, 2020: Novartis establishes its new legal entity in Vietnam 211

6.35 Jan 21, 2020: InterVenn Biosciences expands work in glycoproteomics to successfully target a range of cancers and other indications 211

6.36 Jan 21, 2020: Adaptive announces preliminary unaudited revenue for full year 2019 211

6.37 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 212

6.38 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 212

6.39 Jan 13, 2020: Foundation Medicine appoints Ritesh Khullar as Chief Commercial Officer 213

6.40 Jan 08, 2020: ABBOTT LABORATORIES: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. 214

6.41 Jan 07, 2020: Clovis Oncology announces debt refinancing transaction 214

6.42 Jan 07, 2020: Clovis Oncology announces product revenues for the fourth quarter and full year 2019 215

6.43 Jan 06, 2020: 2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia 215

6.44 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020 216

6.45 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 216

6.46 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 216

6.47 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members 219

6.48 Dec 17, 2019: Vermillion and Einstein Medical Center Philadelphia announce the first patient enrolled in prospective National Clinical Study of Ovarian Cancer Risk detection methods in African American Women 220

6.49 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline 221

6.50 Dec 13, 2019: Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. 221

6.51 Dec 13, 2019: 2cureX presented progression in the IndiTreat immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 222

6.52 Dec 05, 2019: Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day 222

6.53 Nov 26, 2019: LabCorp appoints senior finance executive Jeffrey A. Davis to its Board of Directors 223

7 Appendix 225

7.1 Methodology 225

7.2 About GlobalData 229

7.3 Contact Us 229

List of Tables

Table 1: Ovarian Cancer – Pipeline Products by Stage of Development 16

Table 2: Ovarian Cancer – Pipeline Products by Territory 17

Table 3: Ovarian Cancer – Pipeline Products by Regulatory Path 18

Table 4: Ovarian Cancer – Pipeline Products by Estimated Approval Date 19

Table 5: Ovarian Cancer – Ongoing Clinical Trials 20

Table 6: Ovarian Cancer Companies – Pipeline Products by Stage of Development 21

Table 7: Ovarian Cancer – Pipeline Products by Stage of Development 25

Table 8: 2cureX AB Pipeline Products & Ongoing Clinical Trials Overview 29

Table 9: IndiTreat – OVA – Product Status 29

Table 10: IndiTreat – OVA – Product Description 29

Table 11: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Table 12: Companion Diagnostic Test – Ovarian Cancer – Product Status 30

Table 13: Companion Diagnostic Test – Ovarian Cancer – Product Description 30

Table 14: AB ANALITICA srl Pipeline Products & Ongoing Clinical Trials Overview 31

Table 15: Predictive Biomarker Kit – Ovarian Cancer – Product Status 31

Table 16: Predictive Biomarker Kit – Ovarian Cancer – Product Description 31

Table 17: Accudava Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 18: SEPEX – Product Status 32

Table 19: SEPEX – Product Description 32

Table 20: SETAX – Product Status 33

Table 21: SETAX – Product Description 33

Table 22: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 34

Table 23: ImmunoSEQ Dx – Ovarian Cancer – Product Status 34

Table 24: ImmunoSEQ Dx – Ovarian Cancer – Product Description 34

Table 25: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 35

Table 26: ALM AADx Assay – Product Status 35

Table 27: ALM AADx Assay – Product Description 35

Table 28: Diagnostic Test – Ovarian Cancer – Product Status 36

Table 29: Diagnostic Test – Ovarian Cancer – Product Description 36

Table 30: DNA Damage Response Deficiency Assay – Ovarian Cancer – Product Status 36

Table 31: DNA Damage Response Deficiency Assay – Ovarian Cancer – Product Description 37

Table 32: Angle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 38

Table 33: Multiplex Ovarian Cancer Biomarker Assay – Product Status 38

Table 34: Multiplex Ovarian Cancer Biomarker Assay – Product Description 38

Table 35: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 39

Table 36: Cchek – Ovarian Cancer Confirmatory Test – Product Status 39

Table 37: Cchek – Ovarian Cancer Confirmatory Test – Product Description 39

Table 38: Cchek – Ovarian Cancer Recurrence Test – Product Status 40

Table 39: Cchek – Ovarian Cancer Recurrence Test – Product Description 40

Table 40: Cchek – Ovarian Cancer Screening Test – Product Status 40

Table 41: Cchek – Ovarian Cancer Screening Test – Product Description 41

Table 42: Cchek – Ovarian Cancer Treatment Monitoring Test – Product Status 41

Table 43: Cchek – Ovarian Cancer Treatment Monitoring Test – Product Description 41

Table 44: Anixa Diagnostics Corporation – Ongoing Clinical Trials Overview 42

Table 45: Cchek – Ovarian Cancer Screening Test – The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors 43

Table 46: AroCell AB Pipeline Products & Ongoing Clinical Trials Overview 44

Table 47: TK 210 Assay – Ovarian Cancer – Product Status 44

Table 48: TK 210 Assay – Ovarian Cancer – Product Description 44

Table 49: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 45

Table 50: Finger Stick Test – Ovarian Cancer – Product Status 45

Table 51: Finger Stick Test – Ovarian Cancer – Product Description 45

Table 52: Aspira Labs Pipeline Products & Ongoing Clinical Trials Overview 46

Table 53: OVA1 Plus Test – Product Status 46

Table 54: OVA1 Plus Test – Product Description 46

Table 55: Pelvic Mass Risk Assessment Biomarker Test – Product Status 47

Table 56: Pelvic Mass Risk Assessment Biomarker Test – Product Description 47

Table 57: Aspira Labs – Ongoing Clinical Trials Overview 48

Table 58: Pelvic Mass Risk Assessment Biomarker Test – A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women with Adnexal Mass and High-risk Germline Variants 49

Table 59: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

Table 60: MMD ELISA Test – Ovarian Cancer – Product Status 50

Table 61: MMD ELISA Test – Ovarian Cancer – Product Description 50

Table 62: MMD QPCR Test – Ovarian cancer – Product Status 51

Table 63: MMD QPCR Test – Ovarian cancer – Product Description 51

Table 64: Ovarian Cancer Screening Test – Product Status 51

Table 65: Ovarian Cancer Screening Test – Product Description 52

Table 66: Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 67: OvaDx – Product Status 53

Table 68: OvaDx – Product Description 53

Table 69: Ayanda Biosystems SA (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 54

Table 70: Diagnostic Test – Ovarian Cancer – Product Status 54

Table 71: Diagnostic Test – Ovarian Cancer – Product Description 54

Table 72: BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

Table 73: BARD1 Ovarian Cancer Test – Product Status 55

Table 74: BARD1 Ovarian Cancer Test – Product Description 55

Table 75: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 56

Table 76: Diagnostic Test – Ovarian Cancer – Product Status 56

Table 77: Diagnostic Test – Ovarian Cancer – Product Description 56

Table 78: BioFluidica Microtechnologies LLC Pipeline Products & Ongoing Clinical Trials Overview 57

Table 79: Circulating Tumor Cells Screening Assay – Ovarian Cancer – Product Status 57

Table 80: Circulating Tumor Cells Screening Assay – Ovarian Cancer – Product Description 57

Table 81: Bioindustry Park Silvano Fumero SpA Pipeline Products & Ongoing Clinical Trials Overview 58

Table 82: Diagnostic Kit – Ovarian Cancer – Product Status 58

Table 83: Diagnostic Kit – Ovarian Cancer – Product Description 58

Table 84: Brigham and Women's Hospital Pipeline Products & Ongoing Clinical Trials Overview 59

Table 85: Diagnostic Test – Ovarian Cancer – Product Status 59

Table 86: Diagnostic Test – Ovarian Cancer – Product Description 59

Table 87: Captis Biotechnology Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Table 88: Diagnostic Test – Ovarian Cancer – Product Status 60

Table 89: Diagnostic Test – Ovarian Cancer – Product Description 60

Table 90: Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 61

Table 91: CELsignia Test – Ovarian Cancer – Product Status 61

Table 92: CELsignia Test – Ovarian Cancer – Product Description 61

Table 93: Celula Inc Pipeline Products & Ongoing Clinical Trials Overview 62

Table 94: Diagnostic Test – Ovarian Cancer – Product Status 62

Table 95: Diagnostic Test – Ovarian Cancer – Product Description 62

Table 96: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 63

Table 97: Nanotrap Ovarian Cancer Biomarker Test – Product Status 63

Table 98: Nanotrap Ovarian Cancer Biomarker Test – Product Description 63

Table 99: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 64

Table 100: Diagnostic Test – Ovarian Cancer – Product Status 64

Table 101: Diagnostic Test – Ovarian Cancer – Product Description 64

Table 102: Clarient Inc Pipeline Products & Ongoing Clinical Trials Overview 65

Table 103: Ovatax – Product Status 65

Table 104: Ovatax – Product Description 65

Table 105: ClavGen Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 66

Table 106: Prognostic Assay – Ovarian Cancer – Product Status 66

Table 107: Prognostic Assay – Ovarian Cancer – Product Description 66

Table 108: Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 67

Table 109: Blood-Based Diagnostic Test – Ovarian Cancer – Product Status 67

Table 110: Blood-Based Diagnostic Test – Ovarian Cancer – Product Description 67

Table 111: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 68

Table 112: Ovarian Cancer Diagnostic Panel – Product Status 68

Table 113: Ovarian Cancer Diagnostic Panel – Product Description 68

Table 114: Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 69

Table 115: Biomarker Assay – Ovarian Carcinoma – Product Status 69

Table 116: Biomarker Assay – Ovarian Carcinoma – Product Description 69

Table 117: Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 70

Table 118: B7-H4 Assay – Product Status 70

Table 119: B7-H4 Assay – Product Description 70

Table 120: DcR3 (DD-C248) Assay – Product Status 71

Table 121: DcR3 (DD-C248) Assay – Product Description 71

Table 122: MIC-1 (DD-X065) Assay – Product Status 71

Table 123: MIC-1 (DD-X065) Assay – Product Description 72

Table 124: Spondin-2 (DD-P108) Assay – Product Status 72

Table 125: Spondin-2 (DD-P108) Assay – Product Description 72

Table 126: Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 73

Table 127: OpsisDx Test – Ovarian Cancer – Product Status 73

Table 128: OpsisDx Test – Ovarian Cancer – Product Description 73

Table 129: Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 74

Table 130: Octava Test – Ovarian Cancer – Product Status 74

Table 131: Octava Test – Ovarian Cancer – Product Description 74

Table 132: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 75

Table 133: Liquid Biopsy Test – Ovarian Cancer – Product Status 75

Table 134: Liquid Biopsy Test – Ovarian Cancer – Product Description 75

Table 135: Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 76

Table 136: miRNA test – Ovarian Cancer – Product Status 76

Table 137: miRNA test – Ovarian Cancer – Product Description 76

Table 138: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 77

Table 139: EXOTEST Ovarian Cancer – Product Status 77

Table 140: EXOTEST Ovarian Cancer – Product Description 77

Table 141: Fahy Gurteen UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

Table 142: Diagnostic Test – Ovarian Cancer – Product Status 78

Table 143: Diagnostic Test – Ovarian Cancer – Product Description 78

Table 144: French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 79

Table 145: PTPL1 Based Prognostic Assay – Ovarian Cancer – Product Status 79

Table 146: PTPL1 Based Prognostic Assay – Ovarian Cancer – Product Description 79

Table 147: Ganymed Pharmaceuticals AG Pipeline Products & Ongoing Clinical Trials Overview 80

Table 148: IMAB027 Companion Diagnostic Test – Product Status 80

Table 149: IMAB027 Companion Diagnostic Test – Product Description 80

Table 150: Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 81

Table 151: Mass Spectrometry Based Ovarian Cancer Test – Product Status 81

Table 152: Mass Spectrometry Based Ovarian Cancer Test – Product Description 81

Table 153: Gina-Life Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 82

Table 154: Biomarker Test – Ovarian Cancer – Product Status 82

Table 155: Biomarker Test – Ovarian Cancer – Product Description 82

Table 156: GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 83

Table 157: Diagnostic Assay – Ovarian Cancer – Product Status 83

Table 158: Diagnostic Assay – Ovarian Cancer – Product Description 83

Table 159: H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 84

Table 160: Diagnostic Assay – Ovarian Cancer – Product Status 84

Table 161: Diagnostic Assay – Ovarian Cancer – Product Description 84

Table 162: HealthTell Inc Pipeline Products & Ongoing Clinical Trials Overview 85

Table 163: ImmunoSignature Test – Ovarian Cancer – Product Status 85

Table 164: ImmunoSignature Test – Ovarian Cancer – Product Description 85

Table 165: Hide and Seq Pipeline Products & Ongoing Clinical Trials Overview 86

Table 166: Predictive Assay – Ovarian Cancer – Product Status 86

Table 167: Predictive Assay – Ovarian Cancer – Product Description 86

Table 168: Hudson Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 87

Table 169: Active Ratio Test – Product Status 87

Table 170: Active Ratio Test – Product Description 87

Table 171: Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 88

Table 172: oncoFISH ovarian – Product Status 88

Table 173: oncoFISH ovarian – Product Description 88

Table 174: INEX Innovate Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

Table 175: Xena – Product Status 89

Table 176: Xena – Product Description 89

Table 177: InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 90

Table 178: OncoVue Ovarian – Product Status 90

Table 179: OncoVue Ovarian – Product Description 90

Table 180: InterVenn BioSciences Pipeline Products & Ongoing Clinical Trials Overview 91

Table 181: Blood-Based Diagnostic Test – Ovarian Cancer – Product Status 91

Table 182: Blood-Based Diagnostic Test – Ovarian Cancer – Product Description 91

Table 183: InterVenn BioSciences – Ongoing Clinical Trials Overview 92

Table 184: Blood-Based Diagnostic Test – Ovarian Cancer – Clinical Validation of the InterVenn Ovarian Cancer Liquid Biopsy (VOCAL) 93

Table 185: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 94

Table 186: Biomarker Assay – Ovarian Cancer Chemoresistance – Product Status 94

Table 187: Biomarker Assay – Ovarian Cancer Chemoresistance – Product Description 94

Table 188: Blood Test – Rare Cancer Proteins – Product Status 95

Table 189: Blood Test – Rare Cancer Proteins – Product Description 95

Table 190: Methylation Based Biomarker Assay – Ovarian Cancer – Product Status 95

Table 191: Methylation Based Biomarker Assay – Ovarian Cancer – Product Description 96

Table 192: Multivariate Index Assay – Ovarian Cancer – Product Status 96

Table 193: Multivariate Index Assay – Ovarian Cancer – Product Description 96

Table 194: Protein Biomarker Diagnostic Assay – Ovarian Cancer Chemoresistance – Product Status 97

Table 195: Protein Biomarker Diagnostic Assay – Ovarian Cancer Chemoresistance – Product Description 97

Table 196: KIYATEC Inc Pipeline Products & Ongoing Clinical Trials Overview 98

Table 197: Ovarian Cancer Dx – Product Status 98

Table 198: Ovarian Cancer Dx – Product Description 98

Table 199: Lab Discoveries Ltd Pipeline Products & Ongoing Clinical Trials Overview 99

Table 200: Diagnostic Test – Ovarian Cancer – Product Status 99

Table 201: Diagnostic Test – Ovarian Cancer – Product Description 99

Table 202: Laboratorios SALVAT SA Pipeline Products & Ongoing Clinical Trials Overview 100

Table 203: Diagnostic Kit – Ovarian Cancer – Product Status 100

Table 204: Diagnostic Kit – Ovarian Cancer – Product Description 100

Table 205: Louisville Bioscience Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 101

Table 206: Ovarian Cancer Remission pT Test – Product Status 101

Table 207: Ovarian Cancer Remission pT Test – Product Description 101

Table 208: MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 102

Table 209: Diagnostic Test – Ovarian Cancer 1 – Product Status 102

Table 210: Diagnostic Test – Ovarian Cancer 1 – Product Description 102

Table 211: Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 103

Table 212: Biomarker Test – Ovarian Cancer – Product Status 103

Table 213: Biomarker Test – Ovarian Cancer – Product Description 103

Table 214: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 104

Table 215: Ovarian Mitomic Test – Product Status 104

Table 216: Ovarian Mitomic Test – Product Description 104

Table 217: Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 105

Table 218: Diagnostic Test – Ovarian Cancer – Product Status 105

Table 219: Diagnostic Test – Ovarian Cancer – Product Description 105

Table 220: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 106

Table 221: Immunoassay – Ovarian Cancer – Product Status 106

Table 222: Immunoassay – Ovarian Cancer – Product Description 106

Table 223: MyCartis NV Pipeline Products & Ongoing Clinical Trials Overview 107

Table 224: Diagnostic Test – Ovarian Cancer – Product Status 107

Table 225: Diagnostic Test – Ovarian Cancer – Product Description 107

Table 226: Nagoya University Pipeline Products & Ongoing Clinical Trials Overview 108

Table 227: Biomarker Test – Primary Ovarian Insufficiency – Product Status 108

Table 228: Biomarker Test – Primary Ovarian Insufficiency – Product Description 108

Table 229: Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 109

Table 230: ClarityDX Ovarian – Product Status 109

Table 231: ClarityDX Ovarian – Product Description 109

Table 232: Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 110

Table 233: NBT Diagnostic Test – Ovarian Cancer – Product Status 110

Table 234: NBT Diagnostic Test – Ovarian Cancer – Product Description 110

Table 235: Olink Proteomics AB Pipeline Products & Ongoing Clinical Trials Overview 111

Table 236: Blood Test – Ovarian Cancer – Product Status 111

Table 237: Blood Test – Ovarian Cancer – Product Description 111

Table 238: Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 112

Table 239: Prognostic Test – Ovarian Cancer – Product Status 112

Table 240: Prognostic Test – Ovarian Cancer – Product Description 112

Table 241: Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 113

Table 242: Oncgnostics Diagnostic Test – Ovarian Cancer – Product Status 113

Table 243: Oncgnostics Diagnostic Test – Ovarian Cancer – Product Description 113

Table 244: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 114

Table 245: EarlyCDT – Ovarian Cancer – Product Status 114

Table 246: EarlyCDT – Ovarian Cancer – Product Description 114

Table 247: Oncology Venture U.S. Inc Pipeline Products & Ongoing Clinical Trials Overview 115

Table 248: 2X-131 Companion Diagnostic Assay – Product Status 115

Table 249: 2X-131 Companion Diagnostic Assay – Product Description 115

Table 250: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 116

Table 251: Diagnostic Test – Ovarian Cancer – Product Status 116

Table 252: Diagnostic Test – Ovarian Cancer – Product Description 116

Table 253: OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 117

Table 254: OV Sera Dx – Product Status 117

Table 255: OV Sera Dx – Product Description 117

Table 256: Peregrine Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 118

Table 257: Exosome Based Blood Test – Ovarian Cancer – Product Status 118

Table 258: Exosome Based Blood Test – Ovarian Cancer – Product Description 118

Table 259: Peri Rx Inc Pipeline Products & Ongoing Clinical Trials Overview 119

Table 260: Saliva Test – Ovarian Cancer – Product Status 119

Table 261: Saliva Test – Ovarian Cancer – Product Description 119

Table 262: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 120

Table 263: Diagnostic Assay – Ovarian Cancer – Product Status 120

Table 264: Diagnostic Assay – Ovarian Cancer – Product Description 120

Table 265: Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 121

Table 266: Cancer Risk Stratification Test – Ovarian Cancer – Product Status 121

Table 267: Cancer Risk Stratification Test – Ovarian Cancer – Product Description 121

Table 268: Princess Margaret Cancer Centre Pipeline Products & Ongoing Clinical Trials Overview 122

Table 269: Clinical Screening Tool – Ovarian Cancer – Product Status 122

Table 270: Clinical Screening Tool – Ovarian Cancer – Product Description 122

Table 271: Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 123

Table 272: Diagnostic Assay – Ovarian Cancer – Product Status 123

Table 273: Diagnostic Assay – Ovarian Cancer – Product Description 123

Table 274: Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 124

Table 275: Proteomika Biomarker Test – Ovarian Cancer – Product Status 124

Table 276: Proteomika Biomarker Test – Ovarian Cancer – Product Description 124

Table 277: Provista Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 125

Table 278: Videssa Ovarian – Product Status 125

Table 279: Videssa Ovarian – Product Description 125

Table 280: Queen's University Belfast Pipeline Products & Ongoing Clinical Trials Overview 126

Table 281: Blood Test – Epithelial Ovarian Cancer – Product Status 126

Table 282: Blood Test – Epithelial Ovarian Cancer – Product Description 126

Table 283: Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 127

Table 284: microRNA Test – Ovarian Cancer – Product Status 127

Table 285: microRNA Test – Ovarian Cancer – Product Description 127

Table 286: Shenzhen Mindray Bio-Medical Electronics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 128

Table 287: CL-2000i – HE4 Test – Product Status 128

Table 288: CL-2000i – HE4 Test – Product Description 128

Table 289: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 129

Table 290: SomaSignal Test – Ovarian Cancer – Product Status 129

Table 291: SomaSignal Test – Ovarian Cancer – Product Description 129

Table 292: Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 130

Table 293: Diagnostic SOR-D01 Assay – Ovarian Cancer – Product Status 130

Table 294: Diagnostic SOR-D01 Assay – Ovarian Cancer – Product Description 130

Table 295: Diagnostic SOR-D02 Assay – Ovarian Cancer – Product Status 131

Table 296: Diagnostic SOR-D02 Assay – Ovarian Cancer – Product Description 131

Table 297: Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 132

Table 298: O-TAB Test – Product Status 132

Table 299: O-TAB Test – Product Description 132

Table 300: StageZero Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 133

Table 301: Biomarker Diagnostic Test – Ovarian Cancer – Product Status 133

Table 302: Biomarker Diagnostic Test – Ovarian Cancer – Product Description 133

Table 303: SurExam Life Science & Technology Co. Pipeline Products & Ongoing Clinical Trials Overview 134

Table 304: Diagnostic Test – Ovarian Cancer – Product Status 134

Table 305: Diagnostic Test – Ovarian Cancer – Product Description 134

Table 306: Taizhou ZECEN Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 135

Table 307: HE4 Detection Kit – Product Status 135

Table 308: HE4 Detection Kit – Product Description 135

Table 309: Target Discovery Inc Pipeline Products & Ongoing Clinical Trials Overview 136

Table 310: Isonostic Assay – Ovarian Cancer – Product Status 136

Table 311: Isonostic Assay – Ovarian Cancer – Product Description 136

Table 312: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 137

Table 313: Diagnostic Assay – Ovarian Cancer – Product Status 137

Table 314: Diagnostic Assay – Ovarian Cancer – Product Description 137

Table 315: The University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 138

Table 316: Nanoscale Blood Test – Ovarian Cancer – Product Status 138

Table 317: Nanoscale Blood Test – Ovarian Cancer – Product Description 138

Table 318: Tradewind BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 139

Table 319: Companion Diagnostic Assay – Ovarian Cancer – Product Status 139

Table 320: Companion Diagnostic Assay – Ovarian Cancer – Product Description 139

Table 321: Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 140

Table 322: PolyPEPI 1212 CDx – Product Status 140

Table 323: PolyPEPI 1212 CDx – Product Description 140

Table 324: University of Adelaide Pipeline Products & Ongoing Clinical Trials Overview 141

Table 325: Glycan Test – Ovarian Cancer – Product Status 141

Table 326: Glycan Test – Ovarian Cancer – Product Description 141

Table 327: Luminex Assay – Product Status 142

Table 328: Luminex Assay – Product Description 142

Table 329: University of Arkansas for Medical Sciences Pipeline Products & Ongoing Clinical Trials Overview 143

Table 330: Diagnostic Assay – Epithelial Ovarian Cancer – Product Status 143

Table 331: Diagnostic Assay – Epithelial Ovarian Cancer – Product Description 143

Table 332: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 144

Table 333: Diagnostic Test – Ovarian Cancer – Product Status 144

Table 334: Diagnostic Test – Ovarian Cancer – Product Description 144

Table 335: University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 145

Table 336: Diagnostic Test – Ovarian Cancer – Product Status 145

Table 337: Diagnostic Test – Ovarian Cancer – Product Description 145

Table 338: University of Montreal Pipeline Products & Ongoing Clinical Trials Overview 146

Table 339: Serum Biomarker Test – Ovarian Cancer – Product Status 146

Table 340: Serum Biomarker Test – Ovarian Cancer – Product Description 146

Table 341: University of Pittsburgh Pipeline Products & Ongoing Clinical Trials Overview 147

Table 342: Biomarker Test – Ovarian Cancer – Product Status 147

Table 343: Biomarker Test – Ovarian Cancer – Product Description 147

Table 344: University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 148

Table 345: Biomarker Test – Ovarian Cancer – Product Status 148

Table 346: Biomarker Test – Ovarian Cancer – Product Description 148

Table 347: HMGA2 Based Diagnostic Assay – Ovarian Cancer – Product Status 149

Table 348: HMGA2 Based Diagnostic Assay – Ovarian Cancer – Product Description 149

Table 349: Lysophospholipids Biomarker Assay – Ovarian Cancer – Product Status 149

Table 350: Lysophospholipids Biomarker Assay – Ovarian Cancer – Product Description 150

Table 351: University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 151

Table 352: Diagnostic Assay – Ovarian Cancer – Product Status 151

Table 353: Diagnostic Assay – Ovarian Cancer – Product Description 151

Table 354: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 152

Table 355: Blood-Based Biomarker – Ovarian Cancer – Product Status 152

Table 356: Blood-Based Biomarker – Ovarian Cancer – Product Description 152

Table 357: Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview 153

Table 358: OvaCheck 2 – Product Status 153

Table 359: OvaCheck 2 – Product Description 153

Table 360: Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 154

Table 361: Diagnostic Assay – Ovarian Cancer – Product Status 154

Table 362: Diagnostic Assay – Ovarian Cancer – Product Description 154

Table 363: Wistar Institute Pipeline Products & Ongoing Clinical Trials Overview 155

Table 364: Blood Biomarker Test – Epithelial Ovarian Cancer – Product Status 155

Table 365: Blood Biomarker Test – Epithelial Ovarian Cancer – Product Description 155

Table 366: Yale University Pipeline Products & Ongoing Clinical Trials Overview 156

Table 367: Diagnostic Assay – Ovarian Cancer – Product Status 156

Table 368: Diagnostic Assay – Ovarian Cancer – Product Description 156

Table 369: Targeted Ovarian Cancer Proteome Assay – Product Status 157

Table 370: Targeted Ovarian Cancer Proteome Assay – Product Description 157

Table 371: ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 158

Table 372: Ovarian Cancer Diagnostic Test – Product Status 158

Table 373: Ovarian Cancer Diagnostic Test – Product Description 158

List of Figures

Figure 1: Ovarian Cancer – Pipeline Products by Stage of Development 16

Figure 2: Ovarian Cancer – Pipeline Products by Territory 17

Figure 3: Ovarian Cancer – Pipeline Products by Regulatory Path 18

Figure 4: Ovarian Cancer – Pipeline Products by Estimated Approval Date 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports